endocrine dysfunctions in iron overload in patients with major thalassemia
Authors
abstract
abstract background the aim of the present study was to determine the endocrine dysfunction in patients with major thalassemia, who receive hyper transfusion. materials and methods this cross sectional study was performed during one year, which included 65 major thalassemia patients (31 females and 34 males), aged between 14 month to 27 years old (median 10,3). growth assessment was measured by height and weight according to age and bmi. for all patients serum ferrites concentration, serum calcium and phosphorus, alkaline phosphates, fasting blood sugar, thyroid stimulating hormone, free thyroxin, fsh, lh, dehydroepiandrosterone sulfate, testosterone, estradiol were measured. results in this study, 44.9% of patients were found to be shorter than the height of 5th percentile for their age. diabetes mellitus and impaired fasting glucose were seen in 16% and 28.6% of patients respectively. there was significant correlation between serum ferritin level and impaired glucose tolerance test (p-value =0.043) in them. frequency of hypocalcaemia and hyperphosphatemia were 36.9% and 10.7% respectively. frequency of hypogonadism was 54.8%. fourthy percent of the patients had no endocrine abnormalities. conclusion endocrine dysfunctions are extremely frequent in patients with thalassemia, but chelating therapy can prevent or limit these complications. impaired glucose tolerance was one of the most frequent endocrine complications, which were related to ferritin level. key words endocrine system, beta-thalassemia, ferritins
similar resources
Endocrine Dysfunctions in Iron Overload in Patients with Major Thalassemia
Abstract Background The aim of the present study was to determine the endocrine dysfunction in patients with major thalassemia, who receive hyper transfusion. Materials and Methods This cross sectional study was performed during one year, which included 65 major thalassemia patients (31 females and 34 males), aged between 14 month to 27 years old (median 10,3). Growth assessment was measur...
full textEndocrine Disorders in Beta thalassemia Major Patients
Background Thalassemia is the most common hereditary disorder worldwide. The patient's’ survival is dependent on lifetime blood transfusion which leads to iron overload and its toxicity on various organs including endocrine glands. The study aimed to investigate endocrine disorders in patients with Beta-thalassemia major in the Southern Khorasan province, Iran. Materials and Methods In this des...
full textEndocrine and metabolic disorders in β -thalassemia major patients
Background: Thalassemia is the most common hereditary anemia and beta thalassemia major is its most severe form. Endocrine abnormalities in thalassemia major are common disturbing complications that need prompt management. The purpose of this study was to determine the endocrine disorders and bone mineral density in patients with major -thalassemia in Qazvin, Iran. Methods: In this cross- sect...
full textSequential Deferoxamine - Deferasirox in Treatment of Major Thalassemia with Iron Overload
Abstract Background Iron overload is a major problem in patients with major thalassemia. An effective and safe iron chelator protocol with high compliance rate plays an important role in treatment of these patients. This study was done to assess the efficacy and safety of the sequential deferoxamine and deferasirox protocol in major thalassemia patients in Khuzestan province, Iran. Material ...
full textMyocardial iron overload in thalassemia major. How early to check?
Methods From the 2171 patients enrolled in the MIOT (Myocardial Iron Overload in Thalassemia) network, we retrospectively selected the 35 TM patients aged less than 10 years who had undergone at least one MRI scan. Myocardial iron overload (MIO) was measured by T2* multislice multiecho technique. Biventricular function parameters were quantitatively evaluated in a standard way by cine images. T...
full textTreatment of cardiac iron overload in thalassemia major.
The inexorable tissue iron accumulation in thalas-semia major is well documented and is fatal unless chelation therapy is given to remove the iron from the tissues. Desferal thus revolutionized the treatment of iron overload in thalassemia and dramatically improved survival. Desferal has been widely available now for over two decades and initially it was thought that life expectancy might be op...
full textMy Resources
Save resource for easier access later
Journal title:
iranian journal of pediatric hematology and oncologyجلد ۲، شماره ۲، صفحات ۶۰-۶۶
Keywords
Hosted on Doprax cloud platform doprax.com
copyright © 2015-2023